NR1H4 and Cholestatic liver disease: Decreased hepatic FXR signaling in the context of cholestatic liver disease might be seen as critical because FXR agonists are currently exported as therapeutic strategies in PSC20 and have been shown to be an effective second-line treatment in primary biliary cholangitis.20